upload your CV

Find a job


Napp Pharmaceuticals is a UK-based, privately owned company that is part of a worldwide association of independent pharmaceutical companies that have been developing and providing medicines to patients since the 1920s.

We are a leader in the field of pain control and have been working to further the understanding and treatment of pain for over 30 years. Alongside this heritage, we are committed to becoming a long-term partner to the NHS in respiratory medicine and we have a growing oncology portfolio, currently focused on improving treatment options for blood cancers. Across all our therapy areas, we strive to offer new medicines and initiatives that will support the NHS in delivering effective patient care.

Napp was founded in 1923 by a chemist called Herman Richard Napp and a UK lawyer called Ernest Alfred Clifford. The company was acquired by the current owners in the 1960s, and we remain a privately owned company that is part of a worldwide association of independent companies.

In the 1970s, we manufactured and marketed both over-the-counter and prescription only medicines, including a wide range of antiseptic products. Our most important achievement though was our development of a new controlled release technology called the Continus® system, which we subsequently combined with a variety of existing, effective medicines to bring additional benefits to patients. The first medicine to use the Continus system was a treatment for asthma.

In the 1980s, we launched a revolutionary treatment for chronic cancer pain: the world’s first prolonged release morphine sulphate tablets.

The 1980s also saw the Napp family of companies relocate from three sites around the UK to one site on the Cambridge Science Park occupying the iconic main building, which has become a symbol for the Park. This award winning building was designed by Canadian architect, Arthur Erickson.

In the 1990s, we continued to expand our offering in pain relief, and also introduced prolonged release technology into medicines for cardiovascular diseases. By the end of the 1990s, our success and expansion had led us to occupy a further three buildings around the Science Park.

Throughout the 2000s, we continued to build our reputation as a leader in the field of pain control, introducing further innovations to market, including patches for the treatment of pain. We also launched our first oncology product.

Present day
In 2010, we moved into new buildings on the Science Park, which were designed with our open and collaborative culture in mind, and we have continued to bring new products to UK healthcare professionals and their patients. Since 2010, alongside our ongoing commitment to improving the management of chronic pain, we have re-established ourselves in respiratory medicine with the launch of a new product for asthma, and introduced a second oncology product. At the end of 2013, we were ranked 11th largest pharmaceutical company in the UK based on GP prescription sales.